AI-Powered IHC Quantification Software

Lunit SCOPE IHC Suite is an AI-powered platform that incorporates uIHC, PD-L1, and HER2 analysis tools. It helps biopharma maximize biomarker discovery and companion diagnostic development, support next-generation oncology programs such as ADCs and bispecifics, and scale across cancer types. Enhance efficiency and accuracy with Lunit SCOPE uIHC in analyzing IHC expression.
Pre-clinical & translational

Pre-clinical & translational

Unlock target identification, target validation, and antibody optimization through deeper insights on protein targets.
Biomarker discovery

Biomarker discovery

Get insights on the target expression on a subcellular, cellular, and whole slide level to inform further advancement of biomarker development.
CDx development

CDx development

Use AI-powered IHC analysis to develop innovative biomarkers, scoring methods, and cut-offs tailored to your therapy’s mechanism of action.
Pathologist-assistive solutions

Pathologist-assistive solutions

Enhance productivity and accuracy in analyzing IHC expression across broad cancer types.

Explore Our Suite of
IHC Quantification Solutions

Lunit SCOPE uIHC

Lunit SCOPE uIHC

Accelerate IHC-based CDx development and derisk clinical trials.
For Research Use Only. Not for use in diagnostic procedures or decisions
Lunit SCOPE HER2

Lunit SCOPE HER2

Improve accuracy with AI-assisted ultralow expression analysis.
For Research Use Only. Not for use in diagnostic procedures or decisions
Lunit SCOPE PD-L1

Lunit SCOPE PD-L1

Boost efficiency and improve accuracy with AI-Powered PD-L1 quantification.
For Research Use Only. Not for use in diagnostic procedures or decisions

AI Pathology Software Built to Support Biopharma Innovation

Our digital image analysis software helps biopharma companies scale oncology R&D, advance biomarker strategies, and optimize trials. Lunit is built for end-to-end CDx development, with mature regulatory capabilities, broad scanner and file type compatibility, and scalable deployment across digital pathology platforms and CRO partners.
How We Help Biopharma

Featured News & Publications

Stay informed with the latest research, product updates, and global partnerships driving innovation in AI-powered precision oncology.

See All News & Publications
Media Hub

Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025

Media Hub

Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials

Publication

Leveraging artificial intelligence to predict immune checkpoint inhibitor (ICI) efficacy in proficient MMR mCRC: Translational analyses of AtezoTRIBE and AVETRIC trials

Breakthrough Insights to Drive Success in Drug Development

Breakthrough Insights to Drive Success in Drug Development

Equip your team with IHC quantification software that accelerates biomarker discovery, enhances IHC strategies, and enables scalable deployment.
Contact Us

Frequently Asked Questions

What differentiates Lunit as a partner in AI-powered image analysis?

Our deep expertise, robust clinical evidence, and partnerships with many CROs and digital pathology platform providers set us apart. We prioritize collaboration and offer versatile solutions that are compatible with a wide range of scanners and IMS.